OncologyCE
LECTURECME

Immuno-Oncology Forum III: Focus on NSCLC

Author(s)/Faculty: Roy S. Herbst, MD, PhD; Sarah B. Goldberg, MD, MPH; Leora Horn, MD, MSc; Mark G. Kris, MD
Release Date: 3/1/2018Expiration Date: 2/28/2019
Credit Type: CMENumber of Credits: 1.5
Content Type: LectureProvider:
The rapid evolution and integration of immune checkpoint inhibitors into treatment algorithms for non-small cell lung cancer (NSCLC) has enhanced the progression-free and overall survival of patients with the disease. The rapid development and continued approval of new indications or novel combinations of immunotherapies present many clinical challenges in the selection, treatment, and adverse event management of patients receiving immunotherapy. In this CME Immuno-Oncology Forum, experts in the field will discuss and assess optimal treatment strategies patients with NSCLC, including emerging and established predictive biomarkers, selection of mono- or combination therapy, evaluation of treatment response, as well as the identification and management of therapy-related adverse events.